Intravenous Immunoglobulin
( DrugBank: - / KEGG DRUG: - )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 6 |
| 14 | Chronic inflammatory demyelinating polyneuropathy | 47 |
| 35 | Pemphigus | 2 |
| 38 | Stevens-Johnson syndrome | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 39 | Toxic epidermal necrolysis | 1 |
| 51 | Scleroderma | 16 |
| 309 | Progressive myoclonus epilepsy | 2 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
14. Chronic inflammatory demyelinating polyneuropathy
Clinical trials : 223 / Drugs : 119 - (DrugBank : 28) / Drug target genes : 11 - Drug target pathways : 22
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
35. Pemphigus
Clinical trials : 120 / Drugs : 109 - (DrugBank : 40) / Drug target genes : 28 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
38. Stevens-Johnson syndrome
Clinical trials : 19 / Drugs : 25 - (DrugBank : 10) / Drug target genes : 14 - Drug target pathways : 98
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
39. Toxic epidermal necrolysis
Clinical trials : 15 / Drugs : 16 - (DrugBank : 9) / Drug target genes : 10 - Drug target pathways : 99
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
51. Scleroderma
Clinical trials : 639 / Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
309. Progressive myoclonus epilepsy
Clinical trials : 14 / Drugs : 16 - (DrugBank : 5) / Drug target genes : 7 - Drug target pathways : 16
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
